DCM
PTCT icon

Defilade Capital Management’s PTC Therapeutics PTCT Stock Holding History

Defilade Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.4M Buy
433,699
+57,534
+15% +$4.15M 4.74% 5
2026
Q1 		$25.6M Buy
+376,165
New +$26.6M 3.6% 13

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Defilade Capital Management's PTCT Position: Q2 2026 in Review

Defilade Capital Management increased its PTC Therapeutics (PTCT) stake by 15% in Q2 2026, buying an estimated $4.15M and bringing the position to 433,699 shares worth $35.4M. The position accounts for 4.74% of the portfolio, ranked #5.

Defilade Capital Management first reported a position in PTCT in Q1 2026 and has held it in 2 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Defilade Capital Management held 433,699 shares of PTC Therapeutics worth $35.4M as of Q2 2026.
  • Defilade Capital Management bought 57,534 PTC Therapeutics shares in Q2 2026, an estimated $4.15M.
  • PTC Therapeutics made up 4.74% of Defilade Capital Management's portfolio in Q2 2026, its #5 holding.
  • Defilade Capital Management first reported a position in PTC Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.